Your browser doesn't support javascript.
loading
Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial.
Motzer, Robert J; Russo, Paul; Grünwald, Viktor; Tomita, Yoshihiko; Zurawski, Bogdan; Parikh, Omi; Buti, Sebastiano; Barthélémy, Philippe; Goh, Jeffrey C; Ye, Dingwei; Lingua, Alejo; Lattouf, Jean-Baptiste; Albigès, Laurence; George, Saby; Shuch, Brian; Sosman, Jeffrey; Staehler, Michael; Vázquez Estévez, Sergio; Simsek, Burcin; Spiridigliozzi, Julia; Chudnovsky, Aleksander; Bex, Axel.
Afiliación
  • Motzer RJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10021, USA. motzerr@mskcc.org.
  • Russo P; Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Grünwald V; Clinic for Urology, Clinic for Medical Oncology, University Hospital Essen, Essen, Germany.
  • Tomita Y; Department of Urology and Department of Molecular Oncology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
  • Zurawski B; Department of Outpatient Chemotherapy, Prof. Franciszek Lukaszczyk Oncology Centre, Bydgoszcz, Poland.
  • Parikh O; Rosemere Cancer Centre, Lancashire Teaching Hospitals NHS Trust, Preston, UK.
  • Buti S; Department of Medicine and Surgery, University of Parma, Parma, Italy.
  • Barthélémy P; Medical Oncology Unit, Institut de Cancérologie Strasbourg Europe, Strasbourg, France.
  • Goh JC; ICON Research, South Brisbane, and Queensland University of Technology, Brisbane, QLD, Australia.
  • Ye D; Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Lingua A; Instituto Médico Río Cuarto, Río Cuarto, Argentina.
  • Lattouf JB; Department of Surgery-Urology, CHUM-Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.
  • Albigès L; Department of Cancer Medicine, Gustave Roussy, Villejuif, France.
  • George S; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • Shuch B; University of California, Los Angeles, Los Angeles, CA, USA.
  • Sosman J; Northwestern University Medical Center, Chicago, IL, USA.
  • Staehler M; Interdisciplinary Centre on Renal Tumors, University of Munich, Munich, Germany.
  • Vázquez Estévez S; Hospital Universitario Lucus Augusti (HULA), EOXI de Lugo, Cervo e Monforte, Lugo, Spain.
  • Simsek B; Department of Global Biometrics and Data Science, Bristol Myers Squibb, Princeton, NJ, USA.
  • Spiridigliozzi J; Department of Oncology Late Clinical Global Drug Development, Bristol Myers Squibb, Princeton, NJ, USA.
  • Chudnovsky A; Department of Oncology, Clinical Development, Bristol Myers Squibb, Princeton, NJ, USA.
  • Bex A; Takeda Pharmaceuticals, Boston, MA, USA.
Target Oncol ; 18(5): 639-641, 2023 09.
Article en En | MEDLINE | ID: mdl-37659025
This is a summary of a research article reporting Part A of the CheckMate 914 study (NCT03138512; EudraCT 2016-004502-34). Following surgery to remove renal cell carcinoma (RCC), people with a high risk of the cancer returning received nivolumab plus ipilimumab (adjuvant therapy) or placebo to see if this risk was reduced. The results of this study showed that the risk of RCC returning or death was not changed with adjuvant nivolumab plus ipilimumab treatment compared with placebo. In addition, people treated with nivolumab plus ipilimumab had more side effects compared with people treated with placebo (89% versus 57%).
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Neoplasias Renales Tipo de estudio: Clinical_trials Idioma: En Revista: Target Oncol Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Neoplasias Renales Tipo de estudio: Clinical_trials Idioma: En Revista: Target Oncol Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article